Efficacy of GW320659 in children with attention-deficit/hyperactivity disorder

Veaugh-Geiss, Joseph De; Conners, C. Keith; Sarkis, Elias; Winner, Paul; Ginsberg, Lawrence D.; Hemphill, John M.; Laurenza, Antonio; Asgharnejad, Mahnaz; Webster, CJ; Barrows, C

doi:10.1016/s0924-977x(00)80549-0

European Neuropsychopharmacology

2000

DOI: 10.1016/s0924-977x(00)80549-0

|View full text |Cite

Efficacy of GW320659 in children with attention-deficit/hyperactivity disorder

Joseph De Veaugh-Geiss

C. Keith Conners

Elias Sarkis

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2001

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Response was seen at 1 hour, peaked at 3 hours, and returned to baseline by 8 hours. Clinical efficacy was evaluated in a study of 51 children treated at five centers [27]. Medication dose was sequentially titrated up to 15 mg/d, and was well tolerated.…”

mentioning

confidence: 99%

New treatments and approaches for attention deficit hyperactivity disorder

Newcorn

2001

Curr Psychiatry Rep

View full text Add to dashboard Cite

This has been a very exciting year for clinical trials in child and adolescent psychiatry. Never before has there seemed to be such a concentrated frenzy of activity, with important findings from several federal and industry-sponsored initiatives coming to the fore. Some of these findings have appeared in peer-reviewed journals. Many others were presented at national meetings but have not yet been published. The long lag time between presentation and publication is well-known. However, it is particularly problematic for fields such as pediatric psychopharmacology, in which there is a high demand for new and effective treatments, and off-label prescribing is the rule for many conditions. Because of the high degree of interest in pharmacologic trials in children, and the potential impact of findings from these trials on clinical care now and in the near future, this review not only focuses on findings published in peer-reviewed articles, but also on findings from studies that were peer-reviewed for presentations at national meetings and published in abstract form this past year.Last year's clinical trials review focused on the principal results of the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (ie, the MTA Study). In head-to-head comparison, well-crafted medication treatment, given alone or in combination with a comprehensive behavioral therapy program, was superior to intensive behavioral therapy offered alone (but faded over the course of treatment), or communitystandard care (including medication treatment given outside the study). This finding has received considerable attention in the past year, and rightly so. Yet, the interpretations that medication treatments are preferable for all children with attention deficit hyperactivity disorder (ADHD), and that combination treatment adds little to well-crafted pharmacotherapy (as has been reported in some periodicals), do not do justice to the richness of the study findings. This year, two special sections in the

show abstract

mentioning

confidence: 99%

New treatments and approaches for attention deficit hyperactivity disorder

Newcorn

2001

Curr Psychiatry Rep

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Efficacy of GW320659 in children with attention-deficit/hyperactivity disorder

Cited by 1 publication

References 0 publications

New treatments and approaches for attention deficit hyperactivity disorder

New treatments and approaches for attention deficit hyperactivity disorder

Contact Info

Product

Resources

About